拜塞 .科學+家 結晶研究 210g Crystallized Study

SKU BioSci 201
HK$380.00
In stock
1
Product Details

尿酸結晶

在過去的幾十年裏,已開發國家高尿酸血症和痛風的患病率都在上升,囙此痛風的負擔也在新增。高尿酸血症和痛風與心血管結局的關係以及高尿酸血症干預進一步獲益的機會最近在文獻中被強調。成像科技已被證明是有用的檢測尿酸鹽沉積,甚至之前的第一個臨床症狀,使沉積程度的評估,並提供客觀的量測晶體損耗尿酸降低治療。靶向治療越來越多地被用作治療各種疾病的方法。囙此,針對疾病負擔的不同階段和治療的不同階段,建議了不同的靶點。最終的戰略目標是完全溶解組織中的尿酸鹽晶體,從而避免肌肉骨骼結構的進一步症狀和結構損傷。總之,有證據表明,早期治療痛風和相關的共病是可取的,新的成像科技可能有助於評估特定患者的沉積負擔和對降低尿酸治療的反應,最後,痛風患者醫療保健的最終戰略目標是完全分解尿酸鹽晶體沉積。

Ref: Fernando Perez-Ruiz 1 , Nicola Dalbeth, Tomas Bardin A review of uric acid, crystal deposition disease, and gout. Review Adv Ther . 2015 Jan;32(1):31-41. doi: 10.1007/s12325-014-0175-z. Epub 2014 Dec 23. PMID: 25533440 PMCID: PMC4311063 DOI: 10.1007/s12325-014-0175-z

科學家結晶研究/200毫克/粉劑/瓶裝

可能適合多學科復康調理:

  • 減輕尿酸鈉炎症(1)
  • 高尿酸炎症的改善(2)
  • 尿酸肾结石(3)
  • 痛風性關節炎(4)
  • 高尿酸心血管(5)
  • 尿酸結締鈣化(6)
  • 尿酸鈉冠狀動脈鈣化(7)
  • 焦磷酸鈣結晶溶解(8)
  • 溶解草酸鈣結晶(9)

不適合人士:關節已嚴重變形,甚或已致殘

過程可能:五至十天左右,關節開始感受到略有鬆弛

生活配合:戒口高嘌嚀食品飲料及少吃煎炸烤燒食物,多休息,多喝水

使用週期:

  • 試用2星期沒出現值得鼓舞現象,請停用,建議繼續尋求醫生處理
  • 療程約1-3個月,視乎優化情况,極理想優化後可停用

使用方法:每天二次,每次兩平量匙,餐前或兩歺中間飲用,以溫開水衝開,即可飲用

注意:

  • 本品為營養補充品,不能代替藥物
  • 如有不適反應,建議停止飲用
  • 妊娠期和哺乳期婦女不宜飲用
  • 如不瞭解問題原因或問題持續,請儘快諮詢醫生

重要提示:

不適宜食用:

  • 服用抗凝劑
  • 懷孕或哺乳期
  • 18歲以下兒童
  • 對碳酸氫鉀過敏
  • 嚴重腎功能不全,接受腎透析
  • 對於嚴重或複雜的健康狀況,請在服用前諮詢醫生
  • 嚴重腎功能不全患者慎用
  • 可能出現輕微的胃腸道刺激,如腹部不適、大便不暢或噁心。
  • 肚子不舒服或肚子腫脹
  • 加速阿司匹林等酸性藥物的排泄

檸檬酸鉀副作用:

  • 嚴重腎功能不全患者慎用
  • 可能出現輕微的胃腸道刺激,如腹部不適、大便不暢或噁心。

碳酸氫鉀副作用:

  • 肚子不舒服或肚子腫脹
  • 加速阿司匹林等酸性藥物的排泄
  • 如果出現過敏或不良反應,請停止服用,並立即就醫。
  • 如果出現過敏或不良反應,請停止服用,並立即就醫。

儲存方法:請存放在陰涼乾燥處

原產地:中國香港

成份:軟骨素硫酸鹽(1)、植物皂甙、根提取物、檸檬酸鉀(2)、枸櫞酸三鉀、碳酸氫鉀、綠原酸、咖啡單寧酸、毗黎勒果提取物(3)、L-聚天冬氨酸鈉鹽、辛烷磺酸鈉、三聚磷酸鈉、多磷酸鈉

Uric acid crystal

The prevalence of both hyperuricemia and gout has risen in the last decades in developed countries and therefore the burden of gout has increased. The association of hyperuricemia and gout with cardiovascular outcomes and the opportunity of further benefits of intervention on hyperuricemia have been recently highlighted in the literature. Imaging techniques have proven to be useful for detection of urate deposition, even prior to the first clinical symptoms, enabling the evaluation of the extent of deposition and providing objective measurement of crystal depletion during urate-lowering treatment. Treating to target is increasingly used as the approach to treatment of diverse diseases. Therefore, different targets have been recommended for different stages of the burden of disease and for different stages of treatment. The final strategic target, to which any effort should be taken into consideration, is to completely dissolve urate crystals in tissues and therefore avoid further symptoms and structural damage of involved musculoskeletal structures. In summary, evidence suggest that an early approach to the treatment of gout and associated comorbidities is advisable, that new imaging techniques may help to evaluate both the burden of deposition and response to urate-lowering treatment in selected patients, and finally that the final strategic objective of healthcare for patients with gout is to completely resolve urate crystal deposits.

Ref:

Fernando

Perez-Ruiz 1 ,

Nicola Dalbeth , Tomas Bardin

A review of uric acid, crystal

deposition disease, and gout. Review Adv Ther

. 2015 Jan;32(1):31-41. doi: 10.1007/s12325-014-0175-z. Epub 2014 Dec 23. PMID: 25533440 PMCID: PMC4311063 DOI: 10.1007/s12325-014-0175-z


Scientist Home Crystallized Study

May be suitable for multidisciplinary rehabilitation:

  • Reduce sodium urate inflammation (1)
  • Improvement of hyperuricemia and inflammation (2)
  • Uric acid kidney stones (3)
  • Gouty arthritis (4)
  • High uric acid cardiovascular (5)
  • Uric acid connective calcification (6)
  • Sodium urate coronary artery calcification (7)
  • Crystal dissolution of calcium pyrophosphate (8)
  • Dissolved calcium oxalate crystal (9)

Unsuitable person: the joint has been seriously deformed or even disabled

The process may be: about five to ten days, the joints begin to feel slightly relaxed

Life cooperation: Avoid high purinine food and drink, eat less fried and roasted food, have more rest and drink more water

Life cycle:

  • There is no encouraging phenomenon in the trial for 2 weeks, please stop using it, and it is recommended to continue to seek medical treatment
  • The course of treatment is about 1-3 months. Depending on the optimization, it can be stopped after optimization
  • Usage: twice a day, two spoons each time, drink before meal or between two spoons, rinse with warm water, then drink

Be careful:

  • This product is a nutritional supplement and cannot replace medicine
  • In case of discomfort, it is recommended to stop drinking
  • It is not suitable for pregnant and lactating women
  • If you do not know the cause of the problem or the problem continues, please consult your doctor as soon as possible

Important Note

  1. Not suitable if:
    1. Taking anticoagulants.
    2. Pregnant or lactating.
    3. Children under 18 years of age.
    4. Allergic to Potassium Bicarbonate.
    5. Severe renal dysfunction i.e. undergoing renal dialysis.
  2. For serious or complicated health condition, please seek doctor's advice before taking.
  3. Potassium Citrate side effects:
    1. Use with caution for patients with severe renal insufficiency.
    2. May develop minor gastrointestinal irritation such as abdominal discomfort, loose bowel movements or nausea.
  4. Potassium Bicarbonate side effects:
    1. Upset stomach or swelling of belly.
    2. Accelerate the excretion of acidic drugs such as aspirin.
  5. To stop taking if allergic or adverse reactions occur, and to seek medical help right away.

Storage method: Please store in a cool and dry place

Packaging: 210g per bottle.


Origin: Hong Kong, China

Ingredients: Chondroitin sulfate (1), plant saponins, root extract, potassium citrate (2), Tripotassium citrate, potassium bicarbonate, chlorogenic acid, coffee tannic acid, pirilex fruit extract (3), sodium l-polyaspartate, sodium octanesulfonate, sodium tripolyphosphate, sodium polyphosphate

Major Ingredients

Chondroitin Sulfate, Sapogenins lycosides, Quillaja Extract, Potassium Citrate, Tripotassium Citrate, Potassium Bicarbonate, Kalii Hydrogenocarbonas, Chlorogenic Acid, Igasuric Acid, Terminalia Bellerica Extract, Poly-D-Aspartic Acid, Sodium Salt, Sodium Tripolyphosphate, Armofos, CFA Powder.

參考研究資料: Refs:

  1. Eric W Orlowsky, Thomas V Stabler, Eulàlia Montell, Josep Vergés, and Virginia Byers Kraus. Monosodium urate crystal induced macrophage inflammation is attenuated by chondroitin sulphate: pre-clinical model for gout prophylaxis. BMC Musculoskelet Disord. 2014; 15: 318. Published online 2014 Sep 27. doi: 10.1186/1471-2474-15-318. PMCID: PMC4189145. PMID: 25261974
  2. Zhao-Qing Meng, Zhao-Hui Tang, Yun-Xia Yan, Chang-Run Guo. Study on the Anti-Gout Activity of Chlorogenic Acid: Improvement on Hyperuricemia and Gouty Inflammation. November 2014, The American Journal of Chinese Medicine 42(06):1-13. DOI: 10.1142/S0192415X1450092X
  3. CHARLES Y. C. PAK, KHASHAYAR SAKHAEE, and CINDY FULLER. Successful management of uric acid nephrolithiasis withpotassium citrate. Section on Mineral Metabolism, Department of Internal Medicine, Southwestern Medical School, University of Texas Health Science Centerat Dallas, TX 75235. Kidney international, Vol. 30 (1986), pp. 422—428
  4. Qi Zhou, Shumin Liu,1 Donghua Yua, and Ning Zhang. Therapeutic Effect of Total Saponins from Dioscorea nipponica Makino on Gouty Arthritis Based on the NF-κB Signal Pathway: An In vitro Study. Journal List. Pharmacogn Mag. v.12(47); Jul-Sep 2016. PMC4989800. Pharmacogn Mag. 2016 Jul-Sep; 12(47): 235–240. doi: 10.4103/0973-1296.186344. PMCID: PMC4989800. PMID: 27601855
  5. Angelo L Gaffo,1 N Lawrence Edwards,2 and Kenneth G Saag. Gout. Hyperuricemia and cardiovascular disease: how strong is the evidence for a causal link? Journal List.Arthritis Res Ther. v.11(4); 2009.PMC2745789. Arthritis Res Ther. 2009; 11(4): 240. Published online 2009 Aug 19. doi: 10.1186/ar2761. PMCID: PMC2745789. PMID: 19725932
  6. W Mohr 1 , E Görz. [Mixed tophi. Calcium pyrophosphate dihydrate crystals in gout tophi]. Z Rheumatol. 2000 Aug;59(4):240-4. doi: 10.1007/s003930070066. PMID: 11013985. DOI: 10.1007/s003930070066
  7. Mariano Andres,1Marıa-Amparo Quintanilla,2Francisca Sivera,2JoseSanchez-Paya,3Eliseo Pascual,4Paloma Vela,4and Juan-Miguel Ruiz-Nodar3. Silent Monosodium Urate Crystal Deposits Are AssociatedWith Severe Coronary Calcification inAsymptomatic Hyperuricemia. An Exploratory Study. ARTHRITIS & RHEUMATOLOGY Vol. 68, No. 6, June 2016, pp 1531–1539DOI 10.1002/art.39581
  8. R Cinia, D Chindamob, M Catenacciob, S Lorenzinib, E Selvib, F Neruccib, M P Picchib, G Bertib, R Marcolongob. Dissolution of calcium pyrophosphate crystals by polyphosphates: an in vitro and ex vivo study. http://dx.doi.org/10.1136/ard.60.10.962
  9. Shouwu Guo, Michael D. Ward, Jeffrey A. Wesson. Direct Visualization of Calcium Oxalate Monohydrate Crystallization and Dissolution with Atomic Force Microscopy and the Role of Polymeric Additives. Langmuir 2002, 18, 11, 4284–4291. Publication Date:May 1, 2002. https://doi.org/10.1021/la011754+


This product is not registered under the Pharmacy and Poisons Ordinance or the Chinese Medicine Ordinance. Any claim made for it has not been subject to evaluation for such registration. This product is not intended to diagnose, treat or prevent any disease.

Save this product for later